Hi,
Correct me if I'm wrong but as I understand it, the data is saying this:
1. At albuminuria level of > 500mg/mol = reduction of 18%. (Out of the 40, 26 people had 500mg/mol or higher)
2. Out of the 26, 64% had a reduction of 25% or more in albuminuria level.
3. Across the whole population tested (40), no significant difference between placebo and dmx-200. The reason being both placebo and dmx reduced albuminuria levels. dmx200 showed a reduction of 14% and placebo a reduction of 12% hence no significant difference. Hence, more data is needed to know about legacy effect and why the placebo did good things (-12%).
Data needs some understanding but a careful reading should ease the worries. Management is simply trying to tell us that the result is statistically significant at albuminuria level of 500mg/mmol. Just have to get more data to explain why the placebo also worked. Make no mistake, it's a placebo. If a placebo could do magic like that, we don't need to figure out this disease.
Check the presentation slides and the announcement for confirmation.
Stay cool holders..
- Potential downside will be independent from the results e.g. if any hindrances on REMAP results etc.
- IMO there is plenty of upside.
- Sure it could slide some more if markets keep dropping, but im a happy camper holding.
Can't wait for more explanation. Not many biotech companies at this value going into Phase 3 studies.
- Forums
- ASX - By Stock
- DXB
- Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study
Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study, page-341
-
-
- There are more pages in this discussion • 287 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
(20min delay)
|
|||||
Last
44.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $242.2M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 78 | 44.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
45.0¢ | 28000 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 78 | 0.445 |
2 | 2083 | 0.440 |
3 | 123891 | 0.435 |
4 | 56900 | 0.425 |
5 | 90913 | 0.420 |
Price($) | Vol. | No. |
---|---|---|
0.450 | 28000 | 2 |
0.455 | 45198 | 2 |
0.460 | 50000 | 1 |
0.465 | 138078 | 4 |
0.470 | 101111 | 4 |
Last trade - 09.22am 21/08/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |
Day chart unavailable
The Watchlist
CC9
CHARIOT CORPORATION LTD
MD - Shanthar Pathmanathan, Geologist - David Trabert
MD - Shanthar Pathmanathan
Geologist - David Trabert
SPONSORED BY The Market Online